Direktor: Prof. Dr. med. Alexander Katalinic

Cancer Society, the US Multi-Society Task Force on Colorectal Cancer,
and the American College of Radiology
CA Cancer J Clin, May 1, 2008; 58(3): 130 - 160.
10. Kohne CH, Cunningham D.: Clinical determinants of survival in patients
with 5-fluorouracil-based treatment for metastatic colorectal cancer:
results of a multivariate analysis of 3.825 patients.
Ann Oncol 2002;13:308-317. PM:11886010, Hecht JR, T. Trarbach, E.
Jaeger, J. Hainsworth, R. Wolff, K. Lloyd, G. Bodoky, M. Borner, D.
Laurent, C. Jacques.
11. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow
CD, Woolf SH, Glick SN, Ganiats TG, Bond JH, Rosen L, Zapka JG,
Olsen SJ, Giardello PM, Sisk JE, van Antwerp R, Brown-Davis C,
Marciniak DA, Mayor RJ: Colorectal cancer screening: clinical
guidelines and rationale. Gastroenterology, 1997 59:481-492
12. Journal of Clinical Oncology, 2005: Vol. 23, No. 16S, Le Voyer TE,
Sigurdson E., Hanlon L.: Colon cancer survival is associated with
increasing number of lymph nodes analyzed: A secondary survey of
intergroup trial INT-0089. J Clin Oncol Vol 23, No 34 (December 1),
2005: pp. 8706-8712
13. Landes SH, Murray T, Bolden S, Wingo PA: Cancer statistics,
1999. CA Cancer J Clin 1999 Jan-Feb;49(1):8-31, 1.
14. L. Altenhofen et al: „Projekt wissenschaftliche Begleitung von
Früherkennungs-Koloskopien in Deutschland“, Zentralinstitut für die
kassenärztliche Versorgung, Berlin 2007
15. Mansmann, Ulrich et al.: Bilanz der Qualitätssicherung ambulanter
Koloskopien nach 245.000 Untersuchungen, Dtsch Arztebl 2008;
105(24): 434–40.
16. Liebermann DA, Weiss DG: One-time screening for colorectal cancer
with combined fecal occult-blood testing and examination of the distal
60